Effect of an exercise intervention on aerobic capacity in people with myositis: a waitlist randomised control trial

The University of Sydney0 个研究点目标入组 32 人开始时间: 2024年6月28日最近更新: 2024年7月8日

试验速览

暂无简介。

•Greater than or equal to 18 years of age
•Diagnosis of dermatomyositis, polymyositis or immune-mediated necrotizing myopathy (IMNM), made by a medical practitioner, and in accordance with European league against rheumatism (EULAR)/American college of rheumatology (ACR) Classification Criteria for Adult and Juvenile Idiopathic inflammatory myopathy (IIM) and their Major Subgroups (High probability more than 55% on calculator for IIM).
•Disease duration greater than 3months
•History of significant muscle inflammation (myositis) that has impacted health and been a major consideration in treatment decisions as judged by the treating physician
•Willingness to provide informed consent and willingness to participate and comply with the study requirements
•Deemed safe to exercise according to the Exercise and Sport Science Australia (ESSA) pre-screening form and baseline clinical assessments

•Less than 18 years of age
•Inclusion Body Myositis (IBM)
•Amyopathic Dermatomyositis (ADM)
•Contraindication or inability to exercise as determined by the ESSA pre-screening form and baseline clinical assessments
•Currently pregnant or planning pregnancy
•Diagnosis of condition(s) that may limit ability and safety to perform exercise (e.g., unstable cardiovascular disease, uncontrolled congestive heart failure, known heart failure)
•Active malignancy
•Severe interstitial lung disease (ILD) with a diffusing capacity of the lungs for carbon monoxide (DLCO) <40% and/or a forced vital capacity (FVC) less than 60%
•Renal impairment (estimated glomerular filtration rate (GFR) less than 30mL/min/1.73m2)

发起方